Keyword: Seqirus

Seqirus has teamed up with the Human Vaccines Project's UIVI to advance universal flu vaccine development.

Seqirus' cell-based flu vaccine was 26.5% effective at keeping those 65 and older out of the hospital in the past flu season, an FDA study finds.

Sanofi raised the price of Flublok by 12.5% last year, its only increase above the U.S. National Health Expenditure growth rate.

Thanks to widely used egg-based manufacturing, this fall's flu vaccine will be only 20% effective against the dominant strain, according to a study.

Amid a particularly severe flu season, FDA chief Scott Gottlieb said the "holy grail" of vaccines—a shot that fights any strain of virus—is years off.

CSL’s new brand positioning is actually its first—and it comes after more than 100 years in business.

Flu vaccine specialist Seqirus grew sales 26% in the six months leading up to Dec. 31, driven by a portfolio shift.

Here is some other vaccine news of note for the week.

During the two-plus years of Seqirus' existence, the company has worked to hone its portfolio and boost output of next-gen cell culture flu vaccines.

Seqirus' adjuvanted flu vaccine Fluad is finally set for routine use in the U.K. because the current shot isn't working for the elderly.